Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity

Annals of Hematology

Volumn 82, Issue 9, 2003, Pages 552-557

  Waselenko, Jamie K ^a   Burrows, Ann ^a   Nelson, Douglas A ^b   Lucas, Margaret ^a   Ekstrand, John ^b   Edenfield, William Jeffrey ^a   Myhand, Rick C ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Chronic lymphocytic leukemia; Fludarabine; Hematopoietic stem cell transplantation; Interleukin 2; Neutropenia; Non Hodgkin's lymphoma; Thrombocytopenia

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; CARMUSTINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; RECOMBINANT INTERLEUKIN 2;

ADULT; ANOREXIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG MEGADOSE; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; KAPLAN MEIER METHOD; LYMPHOPROLIFERATIVE DISEASE; MALE; MANTLE CELL LYMPHOMA; MOOD DISORDER; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; ANTIGENS, CD34; CYCLOPHOSPHAMIDE; FEMALE; HEMATOLOGIC DISEASES; HEMATOLOGIC NEOPLASMS; HUMANS; INTERLEUKIN-2; LEUKEMIA, B-CELL, CHRONIC; LEUKOCYTE COUNT; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEUTROPHILS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLATELET COUNT; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVIVAL RATE; VIDARABINE;

EID: 0141617335     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0726-x     Document Type: Article

References (41)

1. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO (1997) High-dose therapy with autologous Hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450
2. Pavletic ZS, Bierman PJ, Vose JM, Bishop MR, Wu CD, Pierson JL et al (1998) High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol 9:1023-1026
3. Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P et al (1996) Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88:2228-2235
4. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC et al (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333
5. Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA et al (1998) The clinical significance of molecular response in indolent follicular lymphomas. Blood 91:2955-2960
6. Johnson S, Smith AG, Loeffler H, Osby E, Juliusson G, Emmerich B et al (1996) Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. The French Cooperative Group on CLL. Lancet 347:1432-1438
7. Robertson LE, Huh Yo, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S et al (1992) Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 80:29-36
8. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757
9. Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T et al (2000) Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96:71-75
10. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A et al (1996) Fludarabine, mitoxantrone, dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268
11. Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK (1997) Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 90:4201-4205
12. Ratanatharathorn R, Uberti J, Karanes C, Abella E, Lum LG, Momin F et al (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84:1050-1055
13. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR et al (1998) Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836
14. Peniket AJ, Ruiz de Elvira MC, Taghipour G et al (1997) Allogeneic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival is worse because of higher treatment related mortality - A report of 764 cases from the EBMT lymphoma registry (Abstract). Blood 90:255a (Abstract 1121)
15. Stein RS, Greer JP, Goodman S, Kallianpur A, Ahmed MS, Wolf SN (1999) High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplantation 23:227-233
16. Oshimi K, Oshimi Y, Akutsu M et al (1986) Cytotoxicity of interleukin-2 activated lymphocytes for leukemia and lymphoma cells. Blood 68:938-948
17. Klingemann H-G (1992) Trying to overcome residual disease after bone marrow transplantation for hematologic malignancies. Leuk Lymphoma 8:421-429
18. Mazumder A (1997) Experimental evidence of interleukin-2 activity in bone marrow transplantation. Cancer J Sci Am 3:S37-S42
19. Zeis M, Uharek L, Glass B, Gaska T, Gassmann W, Mueller-Ruchholtz W (1994) Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts. Bone Marrow Transplantation 14:711-715
20. Massumoto C, Benyunes MC, Sale G (1996) Close simulation of acute graft-versus host disease by interleukin-2 administration after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplantation 17:351-356
21. Pession A, Prete A, Locatelli F, Pierinelli S, Pesson AL, Maccario R et al (1998) Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br J Cancer 78:528-533
22. Messina C, Zambello R, Rossetti F, Gazzola MV, Varottto S, Destro R et al (1996) Interleukin-2 before and/ or after autologous bone marrow transplantation for pediatric acute leukemia patients. Bone Marrow Transplantation 17:729-735
23. Klingemann H-G, Phillips GL (1995) Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia? Leuk Lymphoma 16:397-405
24. Mackall CL, Stein D, Fleisher TA, Brown MR, Hakim FT, Bare CV et al (2000) Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood 96:754-762
25. Lange A, Jazwiec B, Tomaszewska-Toporska B, and Toporski J (1991) Recovery of natural cytotoxicity after bone marrow transplant. Immunol Invest 20:207-213
26. Welte K, Keever CA, Levick J Bonilla MA, Merluzzi VJ, Mertelsmann R et al (1987) Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. patients receiving soybean lectin-separated, and T-cell depleted bone marrow. Blood 70:1595-1603
27. Higuchi CM, Thompson JA, Coc T (1989) Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 49:5509-5513
28. Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A (1991) Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 77:2561-2568
29. Katsanis E, Anderson PM, Filipovich AH, Hasz DE, Rich ML, Loeffler CM et al (1991) Proliferation and cytolytic function of anti-CD3+interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. Blood 78:1286-1291
30. Harris, NL, Jaffe ES, Stein H et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 84:1361-1392
31. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860-1861
32. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234
33. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al (1996) National Cancer Institute-Sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990-4997
34. Vlk V, Eckschlager T, Kavan P, Kabiockova E, Koutecky J, Sobota V et al (2000) Clinical ineffectiveness of IL-2 and/or IFNγ administration after autologous PBSC transplantation in pediatric oncological patients. Pediatr Hematol Oncol 17:31-44
35. Blaise D, Attal M, Pico JL, Reiffers J, Stoppa AM, Bellanger C et al (1997) The use of sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease-free survival of patients with acute leukemia transplanted in first complete remission. Leuk Lymphoma 25:469-478
36. Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf P, McGlave P, Blazar BR et al (1997) Low-dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant 3:34-44
37. Laszlo D, Galieni P, Raspadori D, Scalia G, Bigazzi C, Bocchia M et al (2000) Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non-Hodgkin's lymphoma patients. Leuk Lymphoma 37:157-61
38. Scime R, Indovina A, Santoro A, Musso M, Oliveri A, Tringali S et al (1998) PBSC mobilization, collection, and positive selection in patients with chronic lymphocytic leukemia. Bone Marrow Transplantation 22:1159-1165
39. Itala M, Pelliniemi TT, Rajamaki A, Remes K (1997) Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts yield. Bone Marrow Transplantation 19:647-651
40. Michallet M, Thiebaut A, Dreger P, Remes K, Milpied N, Santini G et al (2000) Peripheral blood stem cell mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukemia: a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukemias Working Party (CLWP). Br J Haematol 108:595-601
41. Watts MJ, Sullivan AN, Leverett D, Peniket AJ, Perry AR, Williams CD et al (1998) Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol 16:1554-1560